NSG mice as hosts for oncological precision medicine.
Journal
Laboratory investigation; a journal of technical methods and pathology
ISSN: 1530-0307
Titre abrégé: Lab Invest
Pays: United States
ID NLM: 0376617
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
04
02
2019
accepted:
14
06
2019
revised:
14
06
2019
pubmed:
15
8
2019
medline:
23
7
2020
entrez:
15
8
2019
Statut:
ppublish
Résumé
Patient-derived xenograft (PDX) models have been rediscovered as meaningful research tool. By using severely immunodeficient mice, high-engraftment rates can be theoretically achieved, permitting clinical stratification strategies. Apart from engraftment efficacy, tolerability towards certain cytostatic drugs varies among individual mouse strains thus impeding large-scale screenings. Here, we aimed at optimizing an in vivo treatment schedule using the widely applied cytostatic drug 5-fluoruracil (5-FU) for exemplary response prediction in colorectal cancer (CRC) PDX models. Four different individual CRC PDX models were engrafted into NOD.Cg-Prkdc
Identifiants
pubmed: 31409886
doi: 10.1038/s41374-019-0298-6
pii: S0023-6837(22)00536-0
doi:
Substances chimiques
Antimetabolites, Antineoplastic
0
Fluorouracil
U3P01618RT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
27-37Références
Lai Y, Wei X, Lin S, Qin L, Cheng L, Li P. Current status and perspectives of patient-derived xenograft models in cancer research. J Hematol Oncol. 2017;10:106.
doi: 10.1186/s13045-017-0470-7
Meehan TF, Conte N, Goldstein T, Inghirami G, Murakami MA, Brabetz S, et al. PDX-MI: minimal information for patient-derived tumor xenograft models. Cancer Res. 2017;77:e62–6.
doi: 10.1158/0008-5472.CAN-17-0582
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat Rev Cancer. 2017;17:254–68.
doi: 10.1038/nrc.2016.140
Xu C, Li X, Liu P, Li M, Luo F. Patient-derived xenograft mouse models: a high fidelity tool for individualized medicine. Oncol Lett. 2019;17:3–10.
pubmed: 30655732
Mullins CS, Bock S, Krohn M, Linnebacher M. Generation of xenotransplants from human cancer biopsies to assess anti-cancer activities of HDACi. Methods Mol Biol. 2017;1510:217–29.
doi: 10.1007/978-1-4939-6527-4_16
Jung J, Seol HS, Chang S. The generation and application of patient derived xenograft (PDX) model for cancer research. Cancer Res Treat. 2017;50:1–10.
doi: 10.4143/crt.2017.307
Shultz LD, Brehm MA, Bavari S, Greiner DL. Humanized mice as a preclinical tool for infectious disease and biomedical research. Ann N Y Acad Sci. 2011;1245:50–4.
doi: 10.1111/j.1749-6632.2011.06310.x
Zhou Q, Facciponte J, Jin M, Shen Q, Lin Q. Humanized NOD-SCID IL2rg –/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett. 2014;344:13–9.
doi: 10.1016/j.canlet.2013.10.015
Zitvogel L, Pitt JM, Daillère R, Smyth MJ, Kroemer G. Mouse models in oncoimmunology. Nat Rev Cancer. 2016;16:759–73.
doi: 10.1038/nrc.2016.91
Gustavsson B, Carlsson G, Machover D, Petrelli N, Roth A, Schmoll H-J, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1–10.
doi: 10.1016/j.clcc.2014.11.002
Rodrigues D, Longatto-Filho A, Martins SF. Predictive biomarkers in colorectal cancer: from the single therapeutic target to a plethora of options. Biomed Res Int. 2016;2016:6896024.
doi: 10.1155/2016/6896024
Devaud N, Gallinger S. Chemotherapy of MMR-deficient colorectal cancer. Fam Cancer. 2013;12:301–6.
doi: 10.1007/s10689-013-9633-z
Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med. 2015;21:1318–25.
doi: 10.1038/nm.3954
Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer. 2010;10:362.
Peltenburg HG, Hermens WT, Willems GM, Flendrig JG, Schmidt E. Estimation of the fractional catabolic rate constants for the elimination of cytosolic liver enzymes from plasma. Hepatology. 1989;10:833–9.
doi: 10.1002/hep.1840100514
Rohde S, Lindner T, Polei S, Stenzel J, Borufka L, Achilles S, et al. Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer. Oncotarget. 2017;8:69756–67.
doi: 10.18632/oncotarget.19263
Sun W, Yan C, Jia S, Hu J. Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients. Int J Clin Exp Med. 2014;7:5857–61.
pubmed: 25664120
pmcid: 4307567
Maletzki C, Huehns M, Knapp P, Waukosin N, Klar E, Prall F, et al. Functional characterization and drug response of freshly established patient-derived tumor models with cpg island methylator phenotype. PLoS ONE. 2015;10:e0143194.
doi: 10.1371/journal.pone.0143194
Maletzki C, Stier S, Gruenert U, Gock M, Ostwald C, Prall F, et al. Establishment, characterization and chemosensitivity of three mismatch repair deficient cell lines from sporadic and inherited colorectal carcinomas. PLoS ONE. 2012;7:e52485.
doi: 10.1371/journal.pone.0052485
Muller MF, Ibrahim AEK, Arends MJ. Molecular pathological classification of colorectal cancer. Virchows Arch. 2016;469:125–34.
doi: 10.1007/s00428-016-1956-3
Kuehn F, Mullins CS, Krohn M, Harnack C, Ramer R, Kramer OH, et al. Establishment and characterization of HROC69—a Crohn s related colonic carcinoma cell line and its matched patient-derived xenograft. Sci Rep. 2016;6:24671.
doi: 10.1038/srep24671
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, et al. Patient derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 2014;4:998–1013.
doi: 10.1158/2159-8290.CD-14-0001
El-Salhy M, Hilding L, Royson H, Tjomsland V. Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil/leukovorin in human colon cancer. Int J Oncol. 2005;27:687–91.
pubmed: 16077917
Dorsey JF, Mintz A, Tian X, Dowling ML, Plastaras JP, Dicker DT, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Mol Cancer Ther. 2009;8:3285–95.
doi: 10.1158/1535-7163.MCT-09-0415
Kang HJ, Lee SH, Price JE, Kim LS. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast J. 2009;15:223–9.
doi: 10.1111/j.1524-4741.2009.00709.x
Chang C-W, Liu C-Y, Lee H-C, Huang Y-H, Li L-H, Chiau J-SC, et al. Lactobacillus casei Variety rhamnosus probiotic preventively attenuates 5-fluorouracil/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model. Front Microbiol. 2018;9:983.
doi: 10.3389/fmicb.2018.00983
Papanastasopoulos P, Stebbing J. Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice. Anticancer Res. 2014;34:1531–5.
pubmed: 24692679
Gross E, Ullrich T, Seck K, Mueller V, de Wit M, von Schilling C, et al. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects. Hum Mutat. 2003;22:498.
doi: 10.1002/humu.9201
Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56:303–16.
doi: 10.4149/neo_2009_04_303
Dean L. Medical Genetics Summaries [Internet]. In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Fluorouracil therapy and DPYD genotype. Bethesda, MD: National Center for Biotechnology Information; 2012. p. 2012–2016.
Roolf C, Richter A, Konkolefski C, Knuebel G, Sekora A, Krohn S, et al. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements. J Hematol Oncol. 2018;11:62.
doi: 10.1186/s13045-018-0607-3
Di Paolo A, Orlandi P, Di Desidero T, Danesi R, Bocci G. Simultaneous, but not consecutive, combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro and in vivo. Oncol Res. 2017;25:1129–40.
doi: 10.3727/096504017X14841698396900
Lecomte T, Ferraz J-M, Zinzindohoue F, Loriot M-A, Tregouet D-A, Landi B, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004;10:5880–8.
doi: 10.1158/1078-0432.CCR-04-0169
Ostwald C, Linnebacher M, Weirich V, Prall F. Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification. Int J Oncol. 2009;35:321–7.
pubmed: 19578746